Nocturnal Hypoglycemia in Type 2 Diabetes

Open access

Abstract

Background and aims: It is known that the majority of critical unacknowledged hypoglycemia has an increased incidence in patients with type 1 diabetes (T1DM) with a long evolution. The aim of this research is to evaluate the variability of glucose level and hypoglycemic events in patients with type 2 diabetes (T2DM) having pharmacological interventions with hypoglycemic risk. These events are sometimes asymptomatic also in T2DM: frequently in elderly, patients with autonomic neuropathy, or having a long evolution of disease.

Material and method: This analysis includes 72 patients with T2DM, with a relative good metabolic control, and possible glucose fluctuations. Glucose variability was appreciated using continuous glucose monitoring systems (CGMS) used for more than 72 hours in hospital or ambulatory setting.

Results: The incidence, duration and severity of hypoglycemia are not correlated with HbA1c value, age, disease duration or treatment. Approximately a quarter of patients had nocturnal hypoglycemia and in 37,5% of events hypoglycemia was prolonged, more 45 minutes. Clinical manifestations in diurnal hypoglycemia were presents in only 40% of the recorded events.

Conclusions: The study suggested that CGMS is beneficial for patients with type 2 diabetes, with hypoglycemic risk and complications, to adjusted medication, education and prevention the cardiovascular events.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. Seaquist ER Anderson J Childs B et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care 36: 1384-1395 2013.

  • 2. Samson WK Stein LM Elrick M et al. Hypoglycemia unawareness prevention: Targeting glucagon production. Physiol Behav 162: 147-50 2016.

  • 3. Silva TP Rolim LC Sallum Filho C Zimmermann LM Malerbi F Dib SA. Association between severity of hypoglycemia and loss of heart rate variability in patients with type 1 diabetes mellitus Diabetes Metab Res Rev 33(2) 2017

  • 4. Jennum P Stender-Petersen K Rabøl R Jørgensen NR Chu PL Madsbad S. The impact of nocturnal hypoglycemia on sleep in subjects with type 2 diabetes. Diabetes Care 38: 2151-2157 2015.

  • 5. Frier BM Schernthaner G HellerS. Hypogly-cemia and cardiovascular risks. Diabetes Care 34: 132-137 2011.

  • 6. Torimoto K Okada Y Mori H Tanaka Y. Relationship between fluctuations in glucose levels measured by continuous glucose monitoring and vascular endothelial dysfunction in type 2 diabetes mellitus. Cardiovascular Diabetology 12:1 2013.

  • 7. Standl E Schnell O Ceriello A. Postprandial hyperglycemia and glycemic variability- should we care? Diabetes Care 34: 120-127 2011.

  • 8. Thompson PL Davis TME. Cardiovascular effects of glucose-lowering therapies for type 2 diabetes: new drugs in perspective. Clin Ther 39: 1012-1025 2017.

  • 9. Mori Y Itoh Y Obata T Tajima N. Effects of pioglitazone vs glibenclamide on postprandial increases in glucose and triglyceride levels and on oxidative stress in Japanese patients with type 2 diabetes. Endocrine 29: 143–148 2006.

  • 10. Cui X Abduljalil D ManorB Peng K Novak V. Multi-Scale Glycemic variability: a link to gray matter atrophy and cognitive decline in type 2 diabetes. PLoS ONE 9(1): e86284 2014

  • 11. Seaquist ER Anderson J Childs B et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care 36: 1384-1395 2013.

  • 12. Samson WKStein LM Elrick M et al. Hypoglycemia unawareness prevention: Targeting glucagon production. Physiol Behav 162: 147-150. 2016

  • 13. Jennum P Stender-Petersen K Rabøl R Jørgensen NR Chu PL Madsbad S. The impact of nocturnal hypoglycemia on sleep in subjects with type 2 diabetes. Diabetes Care 38: 2151-2158 2015.

  • 14. Frier BM Schernthaner G Heller S. Hypogly-cemia and cardiovascular risks. Diabetes Care 34: 132-137 2011.

  • 15. Engler B Koehler C Hoffmann C et al. Relationship between HbA1c on target risk of silent hypoglycemia and glycemic variability in patients with type 2 diabetes mellitus in Exp Clin Endocrinol Diabetes 119: 59-61 2011.

  • 16. Fathi R Haluska B Isbel N et al. The relative importance of vascular structure and function in predicting cardiovascular events. J Am Coll Cardiol 43: 616–623 2004.

  • 17. Alfadhli E Osman E Basri T. Use of a real time continuous glucose monitoring system as an educational tool for patients with gestational diabetes. Diabetol Metab Syndr 26: 48 2016.

  • 18. Toschi E Wolpert H. Utility of continuous glucose monitoring in type 1 and type 2 diabetes in Endocrinol Metab Clin North Am 45: 895-904 2016.

  • 19. Kilpatrick ES Rigby AS Goode K Atkin SL. Relating mean blood glucose and glucose variability to the risk of multiple episodes of hypoglycaemia in type 1 diabetes. Diabetologia 50: 2553-2561 2007.

  • 20. Brod M Christensen T Thomsen TL Bushnell DM. The impact of non-severe hypoglycemic events on work productivity and diabetes management. Value Health 14: 665-671 2011.

  • 21. Levy JC Davies MJ Holman RR 4-T Study- Group. Continuous glucose monitoring detected hypoglycaemia in the Treating to Target in Type 2 Diabetes Trial (4-T). Diabetes Res Clin Pract 131: 161-168 2017.

  • 22. Green JB Bethel MA Armstrong PW et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373: 232–242 2015.

  • 23. Mogensen U Andersson C Fosbøl E et al. Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus–a retrospective nationwide study. Diabetes Obes Metab 16: 1001–1008 2014.

  • 24. Scirica BM Bhatt DL Braunwald E et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369: 1317–1326 2013.

  • 25. Hsu CR Chen YT Sheu WH. Glycemic variability and diabetes retinopathy: a missing link. J Diabetes Complications 29: 302-306 2015.

  • 26. Morioka T Emoto M Tabata T et al. Glycemic control is a predictor of survival for diabetic patients on hemodialysis. Diabetes Care 24: 909–913 2001.

  • 27. Rebrin K Steil GM. Can interstitial glucose assessment replace blood glucose measurement? Diabetes Technol Ther 2: 461-472 2000.

Search
Journal information
Impact Factor


CiteScore 2018: 0.19

SCImago Journal Rank (SJR) 2018: 0.128
Source Normalized Impact per Paper (SNIP) 2018: 0.229

Metrics
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 367 180 6
PDF Downloads 193 100 1